
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Post-streptococcal glomerulonephritis medical therapy
Introduction
Overview
Overview
The mainstay of treatment is pharmacotherapy, however dietary therapy is useful for controlling edema and hypertension. Dietary therapy includes low salt, protein intake, and water restriction. If the streptococcal infection is still present, it should be treated with antibiotics. To control severe hypertension, labetalol is usually used, mild to moderate hypertension, furosemide is used, for rapidly progressive crescentic acute post-streptococcal glomerulonephritis, methylprednisolone is preferred.
Medical therapy
Medical therapy
The mainstay of treatment is pharmacotherapy, however dietary therapy is useful for controlling edema and hypertension
Dietary therapy
Pharmacotherapy
According to 2012 KDIGO guidelines , the following pharmacologic therapy is currently indicated for specific patients with PSGN.[1]
- Diuretics are indicated for adult patients with signs of azotemia or heart failure
- ACE-I or ARBs are indicated for adult patients with persistent proteinuria for > 6 months, especially if > 1g/24hrs
- If the streptococcal infection is still present, it should be treated with antibiotics[2]
- To control severe hypertension, following drugs can be used:
- Preferred regimen: Labetalol 0.5-2 mg/kg/h IV
- If refractory to labetalol then, Preferred regimen: Diazoxide or Nitroprusside 0.5-2 mcg/kg/min IV
- For mild to moderate hypertension:
- Preferred regimen: Furosemide 1-3 mg/kg PO q24h
- For treatment of rapidly progressive crescentic acute post-streptococcal glomerulonephritis, following regimen is used:[3]
- Preferred regimen: Methylprednisolone
References
References
- β Radhakrishnan J, Cattran DC (2012). “The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines–application to the individual patient”. Kidney Int. 82 (8): 840β56. doi:10.1038/ki.2012.280. PMIDΒ 22895519.
- β Zoch-Zwierz W, Wasilewska A, Biernacka A, Tomaszewska B, Winiecka W, WierciΕski R, Porowski T (2001). “[The course of post-streptococcal glomerulonephritis depending on methods of treatment for the preceding respiratory tract infection]”. Wiad. Lek. (in Polish). 54 (1β2): 56β63. PMIDΒ 11344703.
- β Zaffanello M, Cataldi L, Franchini M, Fanos V (April 2010). “Evidence-based treatment limitations prevent any therapeutic recommendation for acute poststreptococcal glomerulonephritis in children”. Med. Sci. Monit. 16 (4): RA79β84. PMIDΒ 20357732.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]
